<DOC>
	<DOCNO>NCT01025622</DOCNO>
	<brief_summary>OBJECTIVE ( S ) : Primary : To assess safety intrahepatic reinfusion increase number autologous highly purified CD133+ stem cell ( SCs ) patient end-stage liver disease . Safety evaluate incidence adverse event ( grade accord WHO ) clinically significant abnormal laboratory value follow reinfusion SCs . Secondary : To assess feasibility immunomagnetic selection autologous CD133+ cell collect leukapheresis peripheral blood ( PB ) patient end-stage liver disease , previously mobilize G-CSF . To assess effect intrahepatic reinfusion highly purified CD133+ cell residual hepatic function patient . STUDY DESIGN : Twelve patient enrol . At first , G-CSF 7.5µg/Kg/b.i.d . administer subcutaneously ( sc ) day 1 completion peripheral blood stem cell ( PBSC ) collection . Harvest bone marrow ( BM ) -derived PBSC begin day + 4 concentration CD133+ cell &gt; 8/uL continued collection target cell dose : 0.5 x 106 CD133+ cells/Kg first 2 cohort patient ; 1 x 106 CD133+ cells/Kg cohort 3 2 x 106 CD133+ cells/Kg cohort 4 ( see definition ) . PB mononuclear cell obtain mobilized standard-volume leukapheresis incubate Macs colloidal superparamagnetic CD133 microbeads CliniMacs device use positive selection CD133+ cell good manufacturing practice ( GMP ) condition . Cryopreservation storage liquid nitrogen perform accord standard procedure . At least 4 week SC mobilization collection , 40 mL single cell suspension highly purify autologous CD133+ cell , obtain rapid thawing , infuse hepatic artery transfemoral transbrachial arteriography . Infusion time lower 15ml/min avoid thrombus formation . The entire procedure perform anesthesiological control . According modify Fibonacci 's increment rule , highly purified G-CSF-mobilized CD133+ cell administer patient start 5x104/Kg patient 's body weight increase every 3 patient . The maximum infused cell dose 1x106/kg . G-CSF 5µg/Kg/day administer sc 3 day reinfusion SCs ( day 0 day +2 ) .</brief_summary>
	<brief_title>Intrahepatic Reinfusion CD133+ Stem Cells Cirrhotic Patients</brief_title>
	<detailed_description>TITLE : Phase I study intrahepatic reinfusion highly purified CD133+ stem cell patient end-stage liver disease . PRINCIPAL INVESTIGATOR : Roberto M. Lemoli , MD CO-INVESTIGATORS : Pietro Andreone , MD , Francesca Bonifazi , MD ; Lucia Catani , BS ; Antonia D'Errico , MD ; Michelangelo Fiorentino , MD ; Valeria Giudice , MD ; Annagiulia Gramenzi , MD ; Elisabetta Loggi , BS ; Stefania Lorenzini , MD ; Francesco Losinno , MD ; Maria Rosa Motta , BS ; Simonetta Rizzi , BS ; Cristina Rossi , MD . STUDY CENTER : Azienda Ospedaliero-Universitaria di Bologna , Policlinico S.Orsola-Malpighi , Bologna - Italia , Unità Operativa di Ematologia collaboration : Unità Operativa di Semeiotica Medica Unità Operativa di Anatomia e Istologia Patologica Unità Operativa di Immunoematologia e Trasfusionale Unità Operativa di Radiologia CLINICAL PHASE : Phase I OBJECTIVE ( S ) : Primary : To assess safety intrahepatic reinfusion increase number autologous highly purified CD133+ stem cell ( SCs ) patient end-stage liver disease . CD133+ SCs previously collect cryopreserved mobilization granulocyte-colony stimulate factor ( G-CSF ) leukapheresis . Safety evaluate incidence adverse event ( grade accord WHO ) clinically significant abnormal laboratory value follow reinfusion SCs . Secondary : To assess feasibility immunomagnetic selection autologous CD133+ cell collect leukapheresis peripheral blood ( PB ) patient end-stage liver disease , previously mobilize G-CSF . To assess effect intrahepatic reinfusion highly purified CD133+ cell residual hepatic function patient . In particular , follow value monitor : synthesis protein ( albumin ) , synthesis factor coagulation ( prothrombin time , INR , fibrinogen , antithrombin III , thromboplastin time ) , bilirubinemia , proliferative activity , biosynthetic capacity ( cholesterol , pseudocholinesterase ) . To assess effect treatment production select cytokine administration G-CSF intrahepatic reinfusion highly purified CD133+ SCs patient end-stage liver disease . STUDY DESIGN : Twelve patient enrol within 18-24 month dose-finding phase . The study design follow : first , G-CSF ( Lenograstim , Aventis Pharma Filgrastim , Amgen ) 7.5µg/Kg/b.i.d . administer subcutaneously ( sc ) day 1 completion peripheral blood stem cell ( PBSC ) collection . Harvest bone marrow ( BM ) -derived PBSC begin day + 4 concentration CD133+ cell &gt; 8/uL continued collection target cell dose : 0.5 x 106 CD133+ cells/Kg first 2 cohort patient ; 1 x 106 CD133+ cells/Kg cohort 3 2 x 106 CD133+ cells/Kg cohort 4 ( see definition ) . PB mononuclear cell obtain mobilized standard-volume leukapheresis incubate Macs colloidal superparamagnetic CD133 microbeads ( Miltenyi Biotec , Bergisch Gladbach , Germany ) CliniMacs device use positive selection CD133+ cell good manufacturing practice ( GMP ) condition ( see attachment ) . Cryopreservation storage liquid nitrogen perform accord standard procedure ( see attachment ) . At least 4 week SC mobilization collection , 40 mL single cell suspension highly purify autologous CD133+ cell , obtain rapid thawing , infuse hepatic artery transfemoral transbrachial arteriography . Infusion time lower 15ml/min avoid thrombus formation . The entire procedure perform anesthesiological control . The intrahepatic route administration deem necessary avoid potential massive spleen trap CD133+ cell conventional intravenous reinfusion cirrhotic patient . Within 24 hour procedure , doppler ultrasonography celiac trunk perform exclude thrombotic event mesenteric district . According modify Fibonacci 's increment rule , highly purified G-CSF-mobilized CD133+ cell administer patient start 5x104/Kg patient 's body weight increase every 3 patient . The maximum infused cell dose 1x106/kg ( see ) . Lenograstim Filgrastim 5µg/Kg/day administer sc 3 day reinfusion SCs ( day 0 day +2 ) expansion induce selective proliferative advantage reinfused cell vivo . NUMBER OF PATIENTS AND TIME FRAME : Twelve patient enrol within 18-24 month dose-finding phase . DIAGNOSIS AND INCLUSION CRITERIA : Signed informed consent . Age &gt; 18 . Karnofsky score &gt; 70 % WHO &lt; 1 . Adequate renal ( serum creatinine &lt; 2 mg/dl ) pulmonary ( Sat O2 &gt; 96 % ) function . Diagnosis advance , end-stage liver disease define Mayo Model End Stage Liver Disease ( MELD ) score 17 25 . Patients follow liver disease etiology enrol study : chronic viral hepatitis B , chronic viral hepatitis C , chronic viral hepatitis D , alcoholic cirrhosis , primary sclerosing cholangitis , primary biliary cirrhosis , Wilson 's disease , genetic haemochromatosis iron over-load cirrhosis , cirrhosis due non alcoholic steato-hepatitis . Patients alcoholic liver cirrhosis withdrawn alcohol active consumption enrol study . Eligibility orthotopic liver transplantation ( OLT ) contraindication enter clinical study . Patients wait list OLT transplantation withdrawn transplant soon suitable donor become available . Their MELD score remain record prior SCs infusion case improvement follow experimental procedure . The presence cirrhosis relate symptom , like ascites , peripheral edema , recurrent gastrointestinal tract bleeding , recurrent encephalopathy represent major contraindication enrol study . The patient may consider eligible clinically stable . EXCLUSION CRITERIA : HIV positivity . Pregnant nursing female . Current uncontrolled infection . Intercurrent organ damage . Diagnosis hepatocarcinoma . Complete portal thrombosis . Severe impairment coagulative function ( PT &lt; 30 % , INR &gt; 2.5 , Platelets &lt; 40x109/L ) would contraindicate artheriography . Grade IV splenomegaly . Budd-Chiari Syndrome sovrahepatic vein thrombosis cirrhosis unknown origin include study .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Signed informed consent Age &gt; 18 year Karnofsky score &gt; 70 % WHO &lt; 1 Adequate renal ( serum creatinine &lt; 2 mg/dl ) pulmonary ( Sat O2 &gt; 96 % ) function Diagnosis advance , endstage liver disease define Mayo Model End Stage Liver Disease ( MELD ) score 17 25 . Patients follow liver disease etiology enrol study : chronic viral hepatitis B , chronic viral hepatitis C , chronic viral hepatitis D , alcoholic cirrhosis ( without alcohol active consumption ) , primary sclerosing cholangitis , primary biliary cirrhosis , Wilson 's disease , genetic hemochromatosis iron overload cirrhosis , cirrhosis due non alcoholic steatohepatitis . Eligibility orthotopic liver transplantation ( OLT ) contraindication enter clinical study . Patients wait list OLT transplantation withdrawn transplant soon suitable donor become available.Their MELD score remain record prior SCs infusion case improvement follow experimental procedure . The presence cirrhosis relate symptom , like ascites , peripheral edema , recurrent gastrointestinal tract bleeding , recurrent encephalopathy represent major contraindication enrol study . The patient may consider eligible clinically stable . HIV positivity Pregnant nursing female Current uncontrolled infection Intercurrent organ damage Diagnosis hepatocarcinoma Complete portal thrombosis Severe impairment coagulative function ( PT &lt; 30 % , INR &gt; 2.5 , Platelets &lt; 40x109/L ) would contraindicate arteriography Grade IV splenomegaly BuddChiari Syndrome sovrahepatic vein thrombosis cirrhosis unknown origin include study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Stem Cells</keyword>
	<keyword>Liver Cirrhosis</keyword>
	<keyword>Cell Therapy</keyword>
</DOC>